Other languages VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.005 ^USD	+0.84%		+3.41%	-46.22%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	Mar. 04
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	Feb. 21
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	Feb. 21
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	Feb. 21
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	23-10-31
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	23-10-26
Top Premarket Gainers	23-10-06
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing	23-10-05
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing	23-10-05
Top Midday Decliners	23-09-29
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29
Top Premarket Decliners	23-09-29
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million	23-09-29
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs	23-09-28
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study	23-09-27
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	23-09-26
MORNING BRIEFING - USA/Asien	23-09-25
Vaccinex to Implement 1-for-15 Reverse Stock Split	23-09-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages VACCINEXPAR

Equities

VCNX

US9186403013

Other languages

Filters